Q2 FY2026 · ended Jun 30, 2026 · Revenue $32.61M, +15.6% YoY · Filed Jul 29, 2026
Anika Therapeutics, Inc. (ANIK) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $32.6 million and net income of $3.3 million. Free cash flow was -$2.1 million. As of Jun 30, 2026 it held $38.4 million in cash and investments and $25.2 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ANIK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 898437
- Former names
- ANIKA THERAPEUTICS INC (until Mar 13, 2014); ANIKA RESEARCH INC (until Nov 27, 1996)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $32.6M | $29.6M | $30.6M | $27.8M | $28.2M |
| Operating income | $3.0M | -$5.5M | $646,000 | -$3.2M | -$4.2M |
| Net income | $3.3M | -$5.1M | $292,000 | -$2.3M | -$4.0M |
| Diluted EPS | $0.24 | -$0.37 | $0.02 | -$0.16 | -$0.28 |
| Operating cash flow | -$684,000 | -$4.8M | $4.6M | $6.9M | -$189,000 |
| Free cash flow | -$2.1M | -$6.3M | $4.0M | $5.0M | -$1.7M |
| Total assets | $183.5M | $179.4M | $190.3M | $189.4M | $187.7M |
| Stockholders' equity | $137.3M | $133.9M | $143.5M | $146.8M | $147.7M |
| Cash and investments | $38.4M | $66.8M | $81.2M | $80.2M | $77.1M |
| Total debt | $25.2M | $25.7M | $26.2M | $24.5M | $25.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 14, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Apr 29, 2026 | Apr 24, 2026 |
All 1004 Anika Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.